Market Overview

Vetr Crowd Sees Juno Therapeutics As A Five-Star Stock

Share:
Vetr Crowd Sees Juno Therapeutics As A Five-Star Stock
  • Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have gained more nearly 30 percent over the past three months, but are lower by more than 10 percent over the past five days.
  • Despite recent weakness in Juno's stock, the Vetr crowd upgraded the issue to four stars out of a possible five.
  • In addition to the strongest stock rating, Vetr's crowd-sourced price target of $58.95 implies a potential upside of more than 16 percent.

The recent decline in Juno's stock isn't deterring the Vetr crowd. On Tuesday, the Vetr crowd upgraded Juno's stock to a five-star rating with a crowd-sourced price target of $58.95 – implying a potential upside of more than 16 percent.

Related Link: Vetr Crowd Upgrades TripAdvisor, 85% Of Users Are Bullish

Seventy-one percent of the Vetr crowd's ratings are bullish, while an approximate equal percentage of the crowd holds a bullish view on Kite Pharma Inc (NASDAQ: KITE) – a peer that is also racing to launch an effective treatment for leukemia and other blood cancers, according to Reuters.

Reuters added that both Juno and Kite have leased factories that they are retooling for future use. In the meantime, both companies are using contract manufacturers for batches of their experimental cells used in clinical trials.

Given the similar ambitions of both companies, it appears the Vetr crowd is more optimistic in Juno's outlook, as Kite's stock is only rated three out of a possible five stars. In addition, the crowd-sourced price target of $75.43 implies an upside of barely 1 percent in Kite's stock.

Latest Ratings for JUNO

DateFirmActionFromTo
Jan 2018Standpoint ResearchDowngradesBuyHold
Jan 2018BarclaysDowngradesOverweightEqual-Weight
Jan 2018Maxim GroupDowngradesBuyHold

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

 

Related Articles (JUNO)

View Comments and Join the Discussion!

Posted-In: cancer Cancer Treatment Juno Therapeutics Kite PharmaUpgrades Crowdsourcing Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
TRMKPiper SandlerMaintains25.0
TCBIPiper SandlerMaintains36.0
OKEB of A SecuritiesMaintains31.0
TBKPiper SandlerMaintains29.0
INFOB of A SecuritiesMaintains94.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com